Evidence & clinical model
A pathway designed by clinicians, evidenced in the literature.
Renvia is not a repackaged consumer wearable. Its clinical logic reflects peer-reviewed cardio-renal-metabolic research and international guideline consensus.
Founder-published research
The pathway is informed by our founder's peer-reviewed work on cardio-renal comorbidity, guideline-directed therapy and remote titration.
Guideline-aligned triggers
Escalation logic is mapped to ESC (heart failure), NICE (T2D and CKD) and KDIGO (renal) recommendations, and is reviewed against annual updates.
Outcome-led KPIs
Every deployment reports admission-avoidance, titration progress, and time-in-therapeutic-range metrics — not vanity engagement scores.
Safety-first design
Renvia is built to DCB0129/DCB0160 clinical safety standards, with a documented clinical safety case for every deployment.
Our clinical model
Human clinicians — supported by, never replaced by, algorithms.
Every escalation Renvia raises is reviewed by a named clinician before action is taken. Algorithms surface signal; the clinical team owns the decision. That's the only responsible way to run a virtual ward for complex, high-risk patients.
Read our security & compliance postureSelected reference domains
Heart failure remote monitoring
Systematic reviews of non-invasive telemonitoring for HFrEF
Cardio-renal syndrome
Mechanistic and clinical literature on type-2 cardio-renal interactions
Diabetic kidney disease
KDIGO 2022 guideline for diabetes management in CKD
Virtual wards
NHS England guidance on virtual ward operating models